title: Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era.
abstract: BACKGROUND
  We describe temporal trends in the mortality rates and factors associated with AIDS and non-AIDS related mortality at the Evandro Chagas Clinical Research Institute (IPEC), Oswaldo Cruz Foundation (FIOCRUZ).
  
  
  METHODS
  Adult patients enrolling from 1986 through 2009 with a minimum follow up of 60 days were included. Vital status was exhaustively checked using patients' medical charts, through active contact with individuals and family members and by linkage with the Rio de Janeiro Mortality database using a previously validated algorithm. The CoDe protocol was used to establish the cause of death. Extended Cox proportional hazards models were used for multivariate modeling.
  
  
  RESULTS
  A total of 3530 individuals met the inclusion criteria, out of which 868 (24.6%) deceased; median follow up per patient was 3.9 years (interquartile range 1.7-9.2 years). The dramatic decrease in the overall mortality rates was driven by AIDS-related causes that decreased from 9.19 deaths/100PYs n 1986-1991 to 1.35/100PYs in 2007-2009. Non-AIDS related mortality rates remained stable overtime, at around 1 death/100PYs. Immunodeficiency significantly increased the hazard of both AIDS-related and non-AIDS-related causes of death, while HAART use was strongly associated with a lower hazard of death from either cause.
  
  
  CONCLUSIONS
  Our results confirm the remarkable decrease in AIDS-related mortality as the HIV epidemic evolved and alerts to the conditions not traditionally related to HIV/AIDS which are now becoming more frequent, needing careful monitoring.
authors.affiliation: Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil. gbeatriz@ipec.fiocruz.br
authors.forename: Beatriz
authors.initials: B
authors.lastname: Grinsztejn
authors.forename: Paula M
authors.initials: PM
authors.lastname: Luz
authors.forename: Antonio G
authors.initials: AG
authors.lastname: Pacheco
authors.forename: Desiree V G
authors.initials: DV
authors.lastname: Santos
authors.forename: Luciane
authors.initials: L
authors.lastname: Velasque
authors.forename: Ronaldo I
authors.initials: RI
authors.lastname: Moreira
authors.forename: Maria Regina C
authors.initials: MR
authors.lastname: Guimarães
authors.forename: Estevão P
authors.initials: EP
authors.lastname: Nunes
authors.forename: Alberto S
authors.initials: AS
authors.lastname: Lemos
authors.forename: Sayonara R
authors.initials: SR
authors.lastname: Ribeiro
authors.forename: Dayse P
authors.initials: DP
authors.lastname: Campos
authors.forename: Marco A A
authors.initials: MA
authors.lastname: Vitoria
authors.forename: Valdilea G
authors.initials: VG
authors.lastname: Veloso
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality*; D000293:Adolescent; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D001938:Brazil / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D013699:Temporal Arteries; D055815:Young Adult